Abstract: The present invention pertains to a process for preparing guanidino acetic acid (GAA) from cyanamide and glycine in alkaline process solution, in which anionic impurities are removed from the process solution by electrodialysis.

Abstract: Process for the separation of a biomolecule containing at least one cationic group from a liquid medium containing said biomolecule, which comprises the use of a tetraphenylborate (TPB) salt.

Abstract: The present invention provides bivalent and multivalent ligands with a view to improving the affinity and pharmacokinetic properties of a urea class of PSMA inhibitors. The compounds and their synthesis can be generalized to multivalent compounds of other target antigens. Because they present multiple copies of the pharmacophore, multivalent ligands can bind to receptors with high avidity and affinity, thereby serving as powerful inhibitors. The modular multivalent scaffolds of the present invention, in one or more embodiments, contains a lysine-based (?-, ?-)dialkyne residue for incorporating two or more antigen binding moieties, such as PSMA binding Lys-Glu urea moieties, exploiting click chemistry and one or more additional lysine residues for subsequent modification with an imaging and/or therapeutic nuclides or a cytotoxic ligands for tumor cell killing.

Abstract: Methods of producing arginine bicarbonate solutions in very high concentrations including reacting an arginine slurry containing a first portion of arginine with a source of carbon dioxide gas at elevated pressure and temperature, adding subsequent portions of arginine to the resulting solution and further reacting with compressed carbon dioxide until a final solution containing in excess of 50% by weight are provided which include preparing an arginine solution by subjecting an arginine water slurry to elevated pressure and temperature and reacting the arginine solution with a source of carbon dioxide gas to form a solution comprising arginine and bicarbonate anion and recovering arginine bicarbonate from the solution.

Abstract: A composition of dipeptides or tripeptides or ester derivatives may be used as a nutritional supplement and to modulate expression of genes associated with healthy maintenance and regulation of muscular and neurological tissue. The compositions include dipeptides and/or tripeptides of branched chain amino acids and optionally include adjuvants, anti-aging compounds and may be provided in a dissolvable powder or liquid form.

Abstract: A method of producing arginine bicarbonate is provided including reacting an arginine slurry with a source of carbon dioxide gas under elevated temperature and low pressure to form a solution of at least 50% arginine bicarbonate, and recovering arginine bicarbonate from the solution.

Abstract: The present invention is directed to the use of isotopically labeled citrulline for diagnosing the presence or absence of a bacterial infection in the lungs of a patient.

Abstract: An aqueous oral spray designed to treat mouth guards against bacterial infection comprising: 1. A naturally derived di-basic amino acid derivative, 2. A natural sweetener which inhibits the adhesion of bacteria to the oral cavity and, 3. Optionally a natural flavor and/or natural dye 4. Optionally a mouth guard surface modified to absorb specific components of above oral aqueous solution so as to render mouth guard more effective overtime in inhibiting microorganism growth on surface and in contact with mouth surfaces compared with unmodified mouth guard surface.

Abstract: The invention relates to novel hemin derivatives of general formula (I), preparing and use thereof as antibacterial and/or antiviral agents, including, as a component in a pharmaceutical compositions. Advantages of the novel antibacterial and antiviral agents based on the hemin derivatives are in their biocompatibility, biodegradability, a high efficacy against resistant bacteria and widespread viruses which are dangerous to humans, and the lack of toxicity.

Abstract: This disclosure teaches the novel use of trifluoroacetamide for N-terminal protection. The disclosure also teaches novel compositions and chemical structures associated therewith. These methods and compositions are useful for site-specific methylation of peptide backbone amides, performed, for example, to modulate the pharmacokinetic properties of peptide drugs.

Abstract: The invention relates to the use of compounds that act on N-alpha acyl glutamine amino acylase enzyme expressed by coryneform bacteria to exert a malodour-counteracting effect, in a composition or article of manufacture suitable for reducing, suppressing or eliminating malodour on inanimate surfaces. The compounds, in particular, may be N-acyl glutamine derivatives.

Abstract: Ligand functionalized substrates, methods of making ligand functionalized substrates, and methods of using functionalized substrates are disclosed.

Abstract: The present invention is to provide a novel polymerizable chiral compound (chiral agent) having high left-handed helical twisting power, a polymerizable liquid crystal composition comprising the polymerizable chiral compound and a polymerizable liquid crystal compound, a liquid crystal polymer, and an optically anisotropic body.

Abstract: The present invention relates to a method of improving the preservation stability of glutathione, which is characterized by allowing glutathione to co-exist with an arginine-acidic amino acid salt. In addition, the present invention relates to a production method of a glutathione preparation, which is characterized by mixing glutathione and an arginine-acidic amino acid salt. By the production method, a glutathione preparation that resists quality deterioration can be provided. Moreover, the present invention relates to a preservation method of glutathione, which is characterized by allowing glutathione to co-exist with an arginine-acidic amino acid salt. By the preservation method, quality deterioration of glutathione during preservation can be suppressed.

Abstract: The present invention relates to novel drug conjugates, where in two drugs are linked together through an appropriate linker having at least two functional groups capable of forming covalent bond with drugs D1 and D2. The invention also relates to developing novel compositions, methods for their preparation and their use in treating various disease conditions.

Abstract: The embodiments herein provide a therapeutic composition comprising N (delta)-protonated L-2-amino-5-diaminomethyleneamino-pentanoic acid called J Factor and a method of ex-vivo synthesis of J-Factor from N(omega)?-protonated L-arginine at a pH of 5-9. The method involves increasing a temperature and or decreasing an acidity of an aqueous solution containing the N(omega)?-protonated L-arginine to obtain a pH value of greater than pKa?2 or less than pKa+2. The derivatives of aqueous solution are allowed to reach an equilibrium state at 25° C. The acidity of the acidity of the aqueous solution is adjusted to a pH value of 7.0 at 25° C. The pKa is a minus logarithm of an acid dissociation constant of the N(omega)?-protonated guanidino group. The N(omega)?-protonated 1-arginine includes ionized forms in the carboxyl or 2-amino group, which are in equilibrium with the N(omega)?-protonated 1-arginine. The composition has a molecular mass of more than or equal to 175.

Abstract: The present invention is directed to the use of isotopically labeled citrulline for gnosing the presence or absence of a bacterial infection in the lungs of a patient.

Abstract: A process for preparation of ?-ketoglutaric acid, L-arginine ?-ketoglutarate 1:1 and 2:1, comprising the steps of: providing a ?-ketoglutaratic acid aqueous solution at an adjusted concentration; adding one equivalent mole of solid L-arginine to the ?-ketoglutaratic acid aqueous solution; stirring and allowing reaction under a controlled temperature; (e) obtaining a resulting L-arginine ?-ketoglutarate 1:1 solution with a pH of approximately 3˜4 or L-arginine ?-ketoglutarate 2:1 solution with a pH of approximately 6.5˜7; and obtaining a final product of L-arginine ?-ketoglutarate 1:1 or 2:1 through spay drying. The yield of the final product is approximately 94% for L-arginine ?-ketoglutarate 1:1 and 97% for L-arginine ?-ketoglutarate 2:1 through the process. Large amount of solvents is eliminated and reaction time is shortened but the yield is increased, hence realizing mass production through reactor in a cost and time effective manner.

Abstract: The invention relates to the use of compounds that act on N-alpha acyl glutamine amino acylase enzyme expressed by coryneform bacteria to exert a malodour-counteracting effect, in a composition or article of manufacture suitable for reducing, suppressing or eliminating malodour on inanimate surfaces. The compounds, in particular, may be N-acyl glutamine derivatives.

Abstract: A manufacturing method for preparing creatine hydrochlorides includes the steps of using absolute ethyl alcohol as the cleaning agent to reduce production costs and to avoid harm to the human body resulting in the production process.

Abstract: A process for preparation of ?-ketoglutaric acid, L-arginine ?-ketoglutarate 1:1 and 2:1 includes the following steps. Provide a ?-ketoglutaratic acid aqueous solution at an adjusted concentration. Add one equivalent mole of solid L-arginine to the ?-ketoglutaratic acid aqueous solution. Stir and allow reaction under a controlled temperature. Obtain a resulting L-arginine ?-ketoglutarate 1:1 solution with a pH of approximately 3˜4 or L-arginine ?-ketoglutarate 2:1 solution with a pH of approximately 6.5˜7. Obtain a final product of L-arginine ?-ketoglutarate 1:1 or 2:1 through spay drying. The yield of the final product is approximately 94% for L-arginine ?-ketoglutarate 1:1 and 97% for L-arginine ?-ketoglutarate 2:1 through the process. Large amount of solvents is eliminated and reaction time is shortened but the yield is increased, hence realizing mass production through reactor in a cost and time effective manner.

Abstract: Methods and compositions for inducing apoptosis of cells, such as macrophages, at a lesioned site of a body vessel are disclosed herein. Nitric oxide can be directly or indirectly delivered to a treatment site to increase macrophage apoptosis. Delivery can include site specific delivery of nitric oxide gas, nitric oxide in aqueous solution or a substance(s) which releases nitric oxide or causes nitric oxide to be generated from an endogenous source. Delivery can be achieved by a delivery system such as a catheter assembly, stent or other suitable device.

Abstract: The present invention relates to metformin glycinate salt and pharmaceutical compositions thereof for the treatment of diabetes mellitus. The method includes administration of the metformin glycinate salt by various routes selected from oral, intravenous injectable, intramuscular injectable, nasal, intraperitoneal, or sublingual, in order to achieve a reduction in blood glucose levels. The invention further relates to the synthesis of a new 1,1-dimethylbiguanide glycinate salt, called Metformin Glycinate. The resulting salt exhibits advantages over other metformin salts. These advantages are due, in the first place, to the fact that the glycine counterion exhibits hypoglycemic effects by itself. Moreover, the salt exhibits more rapid absorption, reaching higher plasma concentrations than those produced with metformin hydrochloride.

Abstract: A marker can determine whether or not a patient has a therapeutic response to an anti-cancer agent. A novel cancer therapy employs the marker. The marker can be N-acetylglucosamine, an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, lauric acid, 6-phosphogluconic acid, butyric acid, 4-methylpyrazole, isobutylamine, glycolic acid, NADH, NAD+, or a substance involved in the metabolism of any of these substances.

Abstract: A process of preparation of ?-ketoglutaric acid for mass production of L-arginine ?-ketoglutarate 1:1 and 2:1 includes the steps of: reacting methyl dichloroacetate and acrylic acid methyl ester with sodium methoxide to obtain Dimethyl 2,2 -dichloroglutarate; reacting the dimethyl 2,2-dichloroglutarate with hydroxide solution to obtain crude ?-ketoglutaric acid aqueous solution; purifying the crude ?-ketoglutaric acid aqueous solution to obtain purified ?-ketoglutaric acid aqueous solution; and adjusting the concentration of the purified ?-ketoglutaric acid aqueous solution by adding water. While avoiding the use of massive organic solvents, the process of the present invention has a remarkable high yield to realize mass production with low manufacturing cost and shortened production time.

Abstract: A novel adjuvant composition is provided that is excellent in safety and convenience as compared to the conventional adjuvant such as Alum. An adjuvant composition comprising citrullines, which are water soluble substance present in the living body, and/or a salt thereof; a vaccine composition comprising said adjuvant composition and an antigen; a process for preparing said adjuvant composition and said vaccine composition; and a method for administering said adjuvant composition and said vaccine composition are provided.

Abstract: L-citrulline or a nutraceutically or pharmaceutically acceptable salt thereof for reducing the kinetics of tumour development or reduce the incidence of tumours in aged humans and animals.

Abstract: Medical foods containing glycomacroprotein and additional supplemented amounts of arginine, leucine, and optionally other amino acids, such as tyrosine, are disclosed. The medical foods can be used to provide the complete protein requirements for patients having metabolic disorders such as phenylketonuria.

Abstract: The present invention relates to the use of guanidinoacetic acid and/or salts thereof as feed additive, in predominantly vegetarian diets, in particular use being made of salts with hydrochloric acid, hydrobromic acid and phosphoric acid. The use proceeds especially in individual doses from 0.01 to 100 g/kg of feed in the form of powders, granules, pastilles or capsules, the feed additive also being able to be used in combination with other physiologically active materials of value. The claimed use which is suitable especially for breeding and growing livestock, has recourse to a compound which is in particular stable in aqueous solution, can be converted to creatine under physiological conditions, and, in contrast to other guanidine derivatives, is completely available to physiological sectors of use.

Abstract: The present invention relates to novel peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.

Abstract: An object of the invention is to provide a novel arginine derivative and a cosmetic satisfactory in compatibility with the skin and hair, excellent in skin softening effect and skin-conditioning effect, and satisfactory in use feeling with little sticky feeling and tense feeling. Such present invention relates to an arginine derivative represented by the following general formula (1): wherein R1 and R2 are a hydrogen atom or a linear or branched monohydroxyalkyl group having 2 to 3 carbon atoms and at least one of R1 and R2 represents a linear or branched monohydroxyalkyl group having 2 to 3 carbon atoms; and R3 represents a hydrogen atom, an alkali metal atom, an ammonium, or an organic ammonium, and a cosmetic containing the same mixed therein.

Abstract: This invention relates in one aspect to non-natural desamino alkyl amino acid compounds, methods of making these compounds, and peptides containing these compounds. In one embodiment, the peptide is neurotensin (8-13) in which the N-terminus is an alpha-desamino, alpha-methyl-N,N-dimethyl-homolysine residue of the invention.

Abstract: Multi-armed, monofunctional, and hydrolytically stable polymers are described having the structure wherein Z is a moiety that can be activated for attachment to biologically active molecules such as proteins and wherein P and Q represent linkage fragments that join polymer arms polya and polyb, respectively, to central carbon atom, C, by hydrolytically stable linkages in the absence of aromatic rings in the linkage fragments. R typically is hydrogen or methyl, but can be a linkage fragment that includes another polymer arm. A specific example is an mPEG disubstituted lysine having the structure where mPEGa and mPEGb have the structure CH3O—(CH2CH2O)nCH2CH2— where n may be the same or different for polya- and polyb- and can be from 1 to about 1,150 to provide molecular weights of from about 100 to 100,000.

Abstract: Described herein are compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as “APPLs”. Such APPLs are deemed useful for a variety of applications, such as, for example, improved nucleotide delivery. Exemplary APPLs include, but are not limited to, compounds of Formula (I), (II), (III), (IV), (V), and (VI), and salts thereof, as described herein: wherein m, n, p, R?, R1, R2, R3, R4, R5, R8, Z, W, Y, and Z are as defined herein.

Abstract: The invention relates to compositions (e.g., nutritional supplements) comprising, consisting essentially of, or consisting of a creatine bicarbonate, and to methods of making and using said compositions.

Abstract: The present invention relates to the field of laboratory diagnostics. Specifically, means and methods for determining the risk of mortality in a patient based on homoarginine and to reduce the risk of mortality by administration of homoarginine are disclosed. Moreover, the present invention relates to the use of homoarginine for the preparation of a medicament for the treatment of a patient having an increased risk of mortality caused by stroke or a cardiac cause. Furthermore, the present application relates to a pharmaceutical composition comprising homoarginine and a composition for foodstuff supplement comprising homoarginine.

Abstract: This invention discloses a method of preservation of a food product comprising the step of adding 1) a first component comprising between 10 ppm and 1% of a biocidal salt of N?—(C1-C22) alkanoyl di-basic amino acid alkyl (C1-C22) ester cationic biocidal molecule with an anionic counterion, and 2) a second component comprising from 10 ppm to 1% by weight an acyl monoglyceride, directly to a food product. The preferred cationic biocidal molecule comprises N?-lauroyl-L-arginine ethyl ester (“LAE”). The invention also discloses the method of preservation of a food product using salts of a N?—(C1-C22) alkanoyl di-basic amino acid alkyl (C1-C22) ester cationic biocidal molecule and an anionic counterion with or without a monoglyceride of a fatty acid, whereby the packaging film is compounded with the salts and the optional monoglyceride of a fatty acid.

Abstract: The present invention is directed to a third generation form of creatine, specifically a creatine hydrochloride salt, that drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while causing fewer negative side effects compared to previous forms of creatine.

Abstract: The present invention describes the use of N6-(1-iminoethyl)-L-lysine for the manufacture of a medicament for the treatment of pulmonary alveolar damage or destruction in mammals, including in humans.

Abstract: Provided herein are compositions and methods useful for the treatment of anhidrosis in mammals, for example, horses.

Abstract: Methods of treating or reducing biofilms, treating a biofilm-related disorder, and preventing biofilm formation using D-amino acids are described.

Abstract: The present invention provides methods to produce arginine bicarbonate more rapidly and efficiently than conventional methods.

Abstract: The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant.

Abstract: Cosmetic or dermatological preparations show improved sensory properties and sufficient microbiological stability due to the addition of benzethonium chloride, methylisothiazolinone, piroctone olamine and/or lauroyl ethyl arginate, the cosmetic or dermatological preparations not comprising any other preservatives, and are especially free of parabens and/or phenoxyethanol.

Abstract: The instant invention relates to peptides obtained from the enzymatic hydrolysis of yellow pea seed proteins that are capable of lowering the blood pressure and reducing the effects of kidney disease in a subject b\ inhibiting or reducing the affinity of the enzymes in the renin-angiotensin system for their substrates, specifically renin, to compositions comprising said peptides and to uses thereof.

Abstract: Disclosed herein are substituted fluoromethanes; pharmaceutical compositions comprising a therapeutically effective amount of the same; processes for preparing these fluoromethanes; and methods of using the same in alleviating infection and parasitism. Also disclosed are methods for identifying substituted fluoromethanes for modulating the activity of receptors and enzymes that bind and/or modify phosphate containing ligands and substrates.

Abstract: A method of producing arginine bicarbonate is provided including reacting an arginine slurry with a source of carbon dioxide gas under elevated temperature and low pressure to form a solution of at least 50% arginine bicarbonate, and recovering arginine bicarbonate from the solution.

Abstract: Methods of producing arginine bicarbonate solutions in very high concentrations including reacting an arginine slurry containing a first portion of arginine with a source of carbon dioxide gas at elevated pressure and temperature, adding subsequent portions of arginine to the resulting solution and further reacting with compressed carbon dioxide until a final solution containing in excess of 50% by weight are provided which include preparing an arginine solution by subjecting an arginine water slurry to elevated pressure and temperature and reacting the arginine solution with a source of carbon dioxide gas to form a solution comprising arginine and bicarbonate anion and recovering arginine bicarbonate from the solution.

Abstract: Provided are methods of detecting the presence or amount of a dihydroxyvitamin D metabolite in a sample using mass spectrometry. The methods generally comprise associating an amine with a dihydroxyvitamin D metabolite in a sample, ionizing the adduct, and detecting the amount of the ion to determine the presence or amount of the vitamin D metabolite in the sample.

Abstract: The present invention provides new addition compounds of guanidinoacetic acid with malic acid, aspartic acid, ascorbic acid, succinic acid, pyruvic acid, fumaric acid, gluconic acid, alpha-ketoglutaric acid, pyroglutamic acid, 3-nicotinic acid, lactic acid, citric acid, maleic acid, acetic acid, formic acid, 2-hydroxybenzoic acid, L-carnitine, acetyl-L-carnitine, taurine, betaine, choline, methionine and lipoic acid as well as in the form of sodium, potassium or calcium guanidinoacetate. These addition compounds have improved physiological and therapeutic properties and are particularly suitable for use as dietary supplements, as animal feeds and in cosmetic or dermatological preparations in which especially the marked stability and good bioavailability of the addition compounds come to the fore.